Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.
View all episodes
